Recent Finacing
Recent Raise
AptaTargets develops aptamer-based therapeutics as antibody alternatives, advancing ApTOLL—an immunomodulator for reducing cerebral inflammation in acute ischemic stroke—toward Phase I/II trials and broader indication applications.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors